OrthoPediatrics (NASDAQ:KIDS) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of OrthoPediatrics (NASDAQ:KIDS) from a hold rating to a sell rating in a report released on Saturday morning.

Several other research analysts also recently weighed in on KIDS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a report on Wednesday, October 8th. Lake Street Capital lowered their price objective on OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, October 10th. JMP Securities cut their target price on OrthoPediatrics from $35.00 to $25.00 and set a “market outperform” rating for the company in a research report on Friday, October 10th. Stifel Nicolaus lowered their price target on OrthoPediatrics from $32.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, October 10th. Finally, Piper Sandler dropped their price target on OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

OrthoPediatrics Trading Down 2.8%

OrthoPediatrics stock opened at $17.07 on Friday. The firm has a 50 day moving average of $17.46 and a 200 day moving average of $19.44. The firm has a market capitalization of $428.12 million, a price-to-earnings ratio of -8.75 and a beta of 1.06. OrthoPediatrics has a 12-month low of $15.28 and a 12-month high of $27.60. The company has a current ratio of 7.40, a quick ratio of 3.52 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Monday, January 9th. The company reported ($0.15) earnings per share for the quarter. The firm had revenue of $25.08 million for the quarter. OrthoPediatrics had a negative net margin of 20.06% and a negative return on equity of 6.86%. As a group, research analysts predict that OrthoPediatrics will post -0.93 earnings per share for the current year.

Institutional Trading of OrthoPediatrics

Several hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. increased its position in OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares during the last quarter. Caption Management LLC bought a new position in shares of OrthoPediatrics in the 3rd quarter valued at about $54,000. BNP Paribas Financial Markets grew its position in OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in OrthoPediatrics during the second quarter worth approximately $220,000. Finally, PDT Partners LLC bought a new stake in shares of OrthoPediatrics in the 1st quarter valued at approximately $244,000. 69.05% of the stock is owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.